Molecular Imaging in Diagnosis of Tumor-induced Osteomalacia

Curr Probl Diagn Radiol. 2019 Jul-Aug;48(4):379-386. doi: 10.1067/j.cpradiol.2018.06.005. Epub 2018 Jun 27.

Abstract

Tumor induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by overproduction of fibroblast growth factor 23 (FGF23) secreted by benign mesenchymal neoplasm. Due to its nonspecific clinical presentation or lack of awareness, the diagnosis of TIO is often significantly delayed resulting in patients' prolonged physical suffering or psychological distress. Successful detection or complete surgical resection of the causative tumor typically leads to rapid resolution of symptoms or reversal of biochemical imbalance. Nuclear medicine and molecular imaging have been playing a promising role as the first-line imaging modalities in the diagnosis and localization of occult FGF23 secreting mesenchymal tumor, especially with the emerging whole-body, head-to-toe Ga68-DOTATATE PET/CT technique. Combined focused diagnostic CT and/or MRI are imperative for accurate delineation of tumor and surgical guidance.

Publication types

  • Review

MeSH terms

  • Aged
  • Female
  • Fibroblast Growth Factor-23
  • Fibroblast Growth Factors / metabolism*
  • Humans
  • Male
  • Middle Aged
  • Molecular Imaging / methods*
  • Neoplasms, Connective Tissue / diagnosis
  • Neoplasms, Connective Tissue / diagnostic imaging*
  • Osteomalacia
  • Paraneoplastic Syndromes
  • Positron Emission Tomography Computed Tomography / methods*
  • Radiographic Image Enhancement*
  • Radiopharmaceuticals
  • Sensitivity and Specificity

Substances

  • FGF23 protein, human
  • Radiopharmaceuticals
  • Fibroblast Growth Factors
  • Fibroblast Growth Factor-23

Supplementary concepts

  • Oncogenic osteomalacia